From MicroPine to HYPE: Hyperion DeFi's Bet on Hyperliquid
From MicroPine to HYPE: Hyperion DeFi's Bet on Hyperliquid
When a biotech upstart pivots into DeFi, you expect turbulence. But Hyperion DeFi (EYEN), formerly Eyenovia, is betting its entire future on the Hyperliquid blockchain — and its latest quarter shows both the promise and fragility of that bet. The company has redefined itself from an ophthalmic drug developer into a 'Triple-Dip' treasury that accumulates HYPE tokens, builds DeFi businesses on Hyperliquid, and shares in ecosystem upside. This is a dramatic transformation, and the Q2 2026 earnings call, held on August 12, 2026, reveals how the company is executing on this pivot while facing real ecosystem shocks.
The Rebrand and the Triple-Dip Strategy
CEO Hyunsu Jung opened the call with a blunt acknowledgment: “Our model is no longer a concept that we ask investors to envision. It has become reality.” — Hyunsu Jung, CEO · 2026-08-12 That reality is a company whose entire operating strategy is now built on Hyperliquid, a fast-growing Layer-1 blockchain for on-chain finance. The company's gross HYPE holdings have increased 56% over the past year, from 1.31M to 2.04M tokens, and its quarterly adjusted gross profit has grown 162% since Q3 2025. The 'Triple-Dip' strategy combines a growing HYPE treasury, scalable DeFi businesses (staking, validator commissions, yield enhancement, DeFi monetization, and ecosystem rewards), and embedded equity/token upside in partner protocols.
The pivot aligns with broader market themes such as Prediction Market expansion and Stablecoin adoption, but Hyperion is taking a concentrated bet. Hyperliquid's own milestones are becoming Hyperion's tailwinds: cumulative protocol revenue surpassed $1 billion, HYPE hit new all-time highs, and the launch of HIP-4 outcome markets is opening a new frontier. As Jung noted, 'Outcome contracts and Hyperliquid trade on the same order book in the same account with materially lower fees at market midpoints than incumbent prediction market venues.'
The USDH Shock and Swift Redeployment
The first real test of this model came in May 2026, when the Hyperliquid ecosystem replaced its native stablecoin USDH with USDC. This forced the wind-down of two core HAUS deployments, releasing 800,000 HYPE that had been locked into those agreements. The financial impact was immaterial—CFO David Knox stated, “we have already redeployed 1 million HYPE tokens into new HAUS partnerships in Q3, and we expect our new deployments over time to position us better than before.” — David Knox, CFO · 2026-08-12 The company quickly announced partnerships with Skew Technologies and Entropy, deploying 500,000 HYPE each. This demonstrates the agility that distinguishes Hyperion from passive treasury vehicles.
The broader global trend toward tokenized assets is also feeding into Hyperion's business. The launch of xStocks on HyperCore, backed by Payward (Kraken's parent), allows on-chain trading of equities like NVIDIA and S&P 500 ETFs, a development Jung highlighted. Hyperion is positioning itself as the institutional gateway for such assets, and its Aviya lending platform has already completed its first institutional credit deal at 8% APY.
Financial Machine and Legacy Exit
Financially, the company continues to reduce its cost base while ramping revenue. Operating expenses excluding stock-based compensation fell 21% quarter-over-quarter to $2.3M, and the company has seen a 46% decline since Q3 2025. The legacy biotech segment has been fully wound down, and in July 2026, Hyperion sold its remaining biotech IP assets to Arctic Vision. David Knox noted, “We are also pleased to announce today that we executed a sale of our remaining biotech IP assets to Arctic Vision in July.” — David Knox, CFO · 2026-08-12 This completes the divestiture of all non-core assets, extinguishing $2.7M of legacy liabilities without cash outlays.
Revenue per segment shows diversification, with staking yield up 69% quarter-over-quarter (driven by HYPE's price appreciation), yield enhancement up 58%, and validator commissions up 4%. The only decline came from DeFi monetization (down 36%) due to the USDH sunset, but management expects recovery as new deployments scale. The company reaffirmed its 2026 adjusted gross profit guidance of $5-7M, with positive cash flow expected by year-end.
Ecosystem Confluence and Outlook
Hyperion's strategy is inherently risky—it is entirely dependent on the success of Hyperliquid. However, the ecosystem is showing remarkable growth, with global attention turning to Tokenized stocks and on-chain prediction markets. As Jung said, 'We continue to lead in designing and deploying strategies that generate differentiated revenues not just on our HYPE Holdings but across key on-chain infrastructure.' The company has also accumulated equity positions in Kinetiq, HyperLend, Silhouette, and Skew, providing optionality on the ecosystem's winners.
What once was is no longer. At Hyperion DeFi, we revamped the company's operating strategy to the accumulation of HYPE and directly building in the Hyperliquid ecosystem.
The contrast with the old Eyenovia is stark. In 2024, the company was discussing FDA meetings and Phase III trials for MicroPine. Today, it is discussing staking yields and validator commissions. The market cap is small—just 15.5 million shares—but the upside, if Hyperliquid continues its trajectory, could be enormous. The company is no longer a biotech waiting for a drug approval; it is a DeFi operator with a proven ability to pivot quickly in a volatile ecosystem. That, perhaps, is the most interesting part of this story: a company that has fully embraced risk and reinvention.